TSE:TH Theratechnologies - TH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$1.07 -0.06 (-5.31%) (As of 03/28/2023 03:59 PM ET) Add Compare Share Share Today's RangeC$1.07▼C$1.1350-Day RangeC$1.00▼C$1.4052-Week RangeC$1.00▼C$3.75Volume16,808 shsAverage Volume24,860 shsMarket CapitalizationC$103.59 millionP/E RatioN/ADividend YieldN/APrice TargetC$3.25 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media About Theratechnologies (TSE:TH) StockTheratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More Receive TH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address TH Stock News HeadlinesMarch 14, 2023 | finance.yahoo.comTheratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor ModelMarch 2, 2023 | finance.yahoo.comTheratechnologies Full Year 2022 Earnings: EPS Misses ExpectationsMarch 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 28, 2023 | finance.yahoo.comTheratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022February 22, 2023 | finance.yahoo.comTheratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIVFebruary 18, 2023 | ca.finance.yahoo.comStocks in play: Theratechnologies Inc.February 16, 2023 | finance.yahoo.comTheratechnologies Announces Path to Resume TH1902 Clinical DevelopmentFebruary 14, 2023 | finance.yahoo.comTheratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business UpdateMarch 28, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 10, 2023 | finance.yahoo.comTheratechnologies Inc. (THTX) Stock Historical Prices & Data - Yahoo FinanceFebruary 9, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED) and Mainz Biomed B.V. (MYNZ)February 8, 2023 | theglobeandmail.comTheratechnologies: Top 10 Undervalued Healthcare Sector Stocks on TSX (TH)January 23, 2023 | marketwatch.comHIV Market 2023 : Advance Technology, Latest Trend and Future Expansion by 2028January 10, 2023 | marketwatch.comGlobal HIV Antiretroviral Drug Market 2023 Size and Growth Analysis by Manufacture, Type, Application, Market Dynamic and Forecast to 2028January 4, 2023 | finance.yahoo.comOpen Letter to Shareholders from CEO Paul LevesqueDecember 23, 2022 | finance.yahoo.comShareholders in Theratechnologies (TSE:TH) are in the red if they invested five years agoDecember 1, 2022 | finance.yahoo.comTheratechnologies Announces Update from Ongoing TH1902 StudyOctober 26, 2022 | finance.yahoo.comTheratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue MicroarraysOctober 13, 2022 | streetinsider.comForm 6-K Theratechnologies Inc. For: Oct 13 - StreetInsider.comOctober 13, 2022 | investing.comTheratechnologies Inc. Tops Q3 EPS by 4c By Investing.com - Investing.comOctober 13, 2022 | benzinga.comTheratechnologies: Q3 Earnings Insights - Theratechnologies (NASDAQ:THTX) - BenzingaOctober 13, 2022 | globenewswire.comTheratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update - GlobeNewswireOctober 13, 2022 | finance.yahoo.comTheratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business UpdateOctober 12, 2022 | benzinga.comEarnings Preview: Theratechnologies - Theratechnologies (NASDAQ:THTX) - BenzingaOctober 12, 2022 | globenewswire.comTheratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium - GlobeNewswireOctober 12, 2022 | finance.yahoo.comTheratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR SymposiumOctober 4, 2022 | nasdaq.comPre-market Movers: FNGR, AERC, FAZE, ARC, ADEA… - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address TH Company Calendar Today3/28/2023Next Earnings (Estimated)4/12/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:TH CUSIPN/A CIKN/A Webwww.theratech.com Phone+1-514-3367800FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price ForecastC$3.25 High Stock Price ForecastC$3.25 Low Stock Price ForecastC$3.25 Forecasted Upside/Downside+203.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.70) Trailing P/E RatioN/A Forward P/E Ratio50.53 P/E Growth-8.5Net IncomeC$-47,240,000.00 Net Margins-59.00% Pretax MarginN/A Return on Equity-1,116.86% Return on Assets-19.74% Debt Debt-to-Equity Ratio562.07 Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual SalesC$80.06 million Price / Sales1.29 Cash FlowC$0.28 per share Price / Cash Flow3.76 Book ValueC($0.23) per share Price / Book-4.65Miscellaneous Outstanding Shares96,810,000Free FloatN/AMarket CapC$103.59 million OptionableNot Optionable Beta1.58 Key ExecutivesMr. Paul Lévesque (Age 59)Pres, CEO & Director Comp: $1.24MMr. Philippe Dubuc M.B.A. (Age 56)MBA, Sr. VP & CFO Comp: $393.59kDr. Christian Marsolais Ph.D. (Age 60)Sr. VP & Chief Medical Officer Comp: $383.71kMr. John Leasure (Age 58)Global Commercial Officer Comp: $353.81kMs. Elif McDonaldSr. Director of Investor RelationsMr. Jocelyn Lafond L.L.M. (Age 55)LL.B., Gen. Counsel & Corp. Sec. Mr. Denis Boucher B.A. (Age 57)L.L.B., VP of Communications & Corp. Affairs Hon. Andre Dupras M.Sc. (Age 59)VP of HR More ExecutivesKey CompetitorsOncolytics BiotechTSE:ONCScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMNovoheartCVE:NVHIntelGenx TechnologiesCVE:IGXView All CompetitorsInsidersJoseph ArenaBought 2,500 shares on 10/21/2022Total: C$6,353.25 ($2.54/share)Jocelyn LafondSold 6,200 sharesTotal: C$17,546.00 ($2.83/share)Jocelyn LafondSold 3,000 sharesTotal: C$8,250.00 ($2.75/share)Joseph ArenaBought 100 shares on 5/2/2022Total: C$293.24 ($2.93/share)View All Insider Transactions TH Stock - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TH shares. View TH analyst ratings or view top-rated stocks. What is Theratechnologies' stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month price objectives for Theratechnologies' stock. Their TH share price forecasts range from C$3.25 to C$3.25. On average, they predict the company's share price to reach C$3.25 in the next twelve months. This suggests a possible upside of 203.7% from the stock's current price. View analysts price targets for TH or view top-rated stocks among Wall Street analysts. How have TH shares performed in 2023? Theratechnologies' stock was trading at C$1.20 at the beginning of 2023. Since then, TH stock has decreased by 10.8% and is now trading at C$1.07. View the best growth stocks for 2023 here. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 12th 2023. View our TH earnings forecast. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), Theratechnologies (THERF), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Endeavour Mining (EDV), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and Avigilon (AVO). What is Theratechnologies' stock symbol? Theratechnologies trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TH." How do I buy shares of Theratechnologies? Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Theratechnologies' stock price today? One share of TH stock can currently be purchased for approximately C$1.07. How much money does Theratechnologies make? Theratechnologies (TSE:TH) has a market capitalization of C$103.59 million and generates C$80.06 million in revenue each year. The company earns C$-47,240,000.00 in net income (profit) each year or C($0.70) on an earnings per share basis. How can I contact Theratechnologies? Theratechnologies' mailing address is 2015 Peel St 5th Floor, MONTREAL, QC H3A 1T8, Canada. The official website for the company is www.theratech.com. The company can be reached via phone at +1-514-3367800. This page (TSE:TH) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.